Updated:
Humana shares rose 1.4% in premarket trading on Wednesday, October 7, after Cantor Fitzgerald upgraded the health insurer to Overweight from Neutral and lifted its price target to $460 from $300. The analyst cited improving confidence in Humana’s prospects for recovering Medicare Advantage margins and strengthening its Medicare quality ratings.
The call adds to a series of more positive analyst views on the company, whose earnings are closely tied to the performance of its Medicare Advantage business. Cantor also raised its earnings forecasts for 2027 and 2028, while Humana’s newly available 2027 insurance plans bring the company into the approaching annual Medicare enrollment period.
Cantor raises its earnings outlook
Cantor increased its estimated adjusted earnings per share for Humana to $17.96 for 2027, from $15.86, and to $28.27 for 2028, from $25.38. The firm said the revised forecasts followed conversations with large Medicare Advantage providers and industry experts about star ratings and insurers’ plan-bidding strategies.
According to same-day reporting by Investing.com, Cantor argued that Humana’s share price did not fully reflect a potential two-year improvement in Medicare Advantage margins. Its valuation comparison used an implied 2028 earnings midpoint; that is an analyst framework, not company-reported earnings guidance. Humana’s future results will depend on operating performance and the economics of its government-sponsored plans.
The target-price increase reflects Cantor’s changed assessment, rather than a new financial forecast from Humana. It is also distinct from the premarket share move: the 1.4% gain described the stock’s early trading, while the $460 figure was the analyst’s 12-month price target.
Medicare Advantage margins remain central
Medicare Advantage plans are offered by private insurers under the federal Medicare program. For companies such as Humana, profitability can be affected by the payments received for members, the cost of their medical care, enrollment and the design of benefits. That makes expected margins a key factor in analysts’ estimates of future earnings.
Star ratings are another important part of the outlook. Medicare uses ratings to assess plan quality, and ratings can influence quality-related bonus payments to insurers. Cantor’s upgrade therefore rests partly on its expectation that Humana can improve its ratings and margins; those outcomes have not been established by the analyst’s revised forecasts.
Other analysts have also turned more positive
The Cantor move follows a late-September upgrade by Barclays, which shifted Humana to Overweight from Equal Weight and set a $515 target, according to the October 7 Investing.com report. Wolfe Research had maintained an Outperform rating with a $450 target, the same report said. These are separate analyst opinions and do not guarantee that the company will meet the assumptions behind them.
The premarket advance came as major U.S. stock indexes were lower before the regular session, according to Investing.com’s account of Wednesday trading. Humana’s move was therefore notable against that early market backdrop, although the brief report did not establish how the shares performed later in the session.
2027 plans enter the enrollment window
Humana’s 2027 Medicare Advantage offerings, announced earlier in October, include plans with $0 in-network primary care and laboratory services, according to the source report. The company’s plan materials and benefits vary by plan and location, so the listed features should not be read as applying uniformly to every member or market.
The annual Medicare enrollment period is scheduled to run from October 15 through December 7, 2026, according to the Centers for Medicare & Medicaid Services. The period gives eligible people an opportunity to review coverage options for 2027. Humana’s plan offerings provide relevant commercial context for the insurer’s Medicare business, but the reports available do not establish that the product announcement itself caused Wednesday’s share gain.
What remains uncertain
The immediate catalyst identified in the October 7 report was Cantor Fitzgerald’s rating and forecast change. The report did not provide a Humana response to the upgrade, revised company guidance, or evidence that the analyst’s projected margin recovery had already occurred. Nor did it establish whether Humana would reach Cantor’s earnings estimates or price target.
Investors will be able to assess the new plans as enrollment proceeds, while the company’s future results and star-rating performance remain key uncertainties behind the bullish analyst case. Wednesday’s premarket rise reflected the rating news at that point in trading, not confirmation of the longer-term recovery Cantor expects.
